Preclinical Molecular PET-CT Imaging Targeting CDCP1 in Colorectal Cancer

Figure 2

CDCP1 targeted molecular PET-CT imaging detects a CRC cell line xenograft. (a) Diagram of HCT116 cell inoculation followed by a period of tumor growth, radioligand administration PET-CT imaging. (b) Representative H&E staining (left) and anti-CDCP1 immunohistochemical staining (right) demonstrating strong plasma membrane staining of CDCP1 on malignant cells in subcutaneous HCT116 cell xenograft tumors in mice (magnification 40X; scale bar 50 μm). (c) Representative 3D PET-CT imaging reconstructions of mice bearing subcutaneous HCT116 cell xenografts administered i.v.⁸⁹Zr-10D7, unlabelled 10D7 with ⁸⁹Zr -10D7, or ⁸⁹Zr-IgG1κ (1.4MBq) at 1, 24, 48, 72, and 144 hours after administration. (d) Graph of the time course of in vivo PET avidity of HCT116 cell xenograft tumor, heart, lungs, and liver at 1, 24, 48, 72, and 144 h after i.v. administration of ⁸⁹Zr-10D7, unlabelled 10D7 with ⁸⁹Zr -10D7, and ⁸⁹Zr-IgG1κ. Error bars are present for ⁸⁹Zr-IgG1κ but at the scale are too small to be apparent. (e) Graph of radioactivity of recovered tumors measured by ex vivo radiometric analysis and displayed as %ID/g. , .

(a)

(b)

(c)

(d)

(e)